Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $10,820.50 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 425 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $25.46, for a total value of $10,820.50. Following the completion of the sale, the executive vice president now owns 262,198 shares in the company, valued at $6,675,561.08. The trade was a 0.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $25.83 on Friday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -24.37 and a beta of 2.04. BioLife Solutions, Inc. has a 52-week low of $14.84 and a 52-week high of $29.55. The stock’s 50 day moving average price is $26.66 and its two-hundred day moving average price is $25.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. The firm had revenue of $22.71 million for the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. During the same period in the prior year, the business earned ($0.21) EPS. On average, equities analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Institutional Trading of BioLife Solutions

Hedge funds have recently bought and sold shares of the business. Steward Partners Investment Advisory LLC acquired a new stake in BioLife Solutions in the 4th quarter valued at $26,000. Mark Sheptoff Financial Planning LLC acquired a new stake in BioLife Solutions in the 3rd quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BioLife Solutions in the 4th quarter valued at $31,000. Quest Partners LLC acquired a new stake in BioLife Solutions in the 3rd quarter valued at $57,000. Finally, 1620 Investment Advisors Inc. grew its position in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 675 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. KeyCorp upped their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Northland Securities upped their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. HC Wainwright upped their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a report on Thursday. Finally, Benchmark reiterated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.